CHA Vaccine Research Institute Co., Ltd. operates as a research-oriented biotechnology company. The firm involves in research and development of vaccine products targeting infectious disease as well as chronic disease. It specializes in proprietary vaccine adjuvant L-pampo and recombinant antigen development platform. The company was founded by Hong Mo Moon on June 13, 2000 and is headquartered in Seongnam-si, South Korea.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company